Related Experiment Video
Updated: Aug 5, 2026
09:25
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
How Much Do Healthcare Practitioners Know About Sarcoma?
Motaz Alaqeel1, Saad M Alangari2, Abdulrahman Ahmed Almebki1
1Department of Orthopedic Surgery, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia.
Current Oncology (Toronto, Ont.)
|July 27, 2026
Summary
Healthcare practitioner awareness of sarcoma is limited, impacting early diagnosis. Targeted education and clearer referral pathways are crucial for timely soft tissue and bone sarcoma management.
Area of Science:
- Oncology
- Medical Education
Background:
- Limited sarcoma awareness among healthcare practitioners hinders early detection and management of soft tissue and bone sarcomas.
- Diagnostic delays in sarcoma are a significant concern, necessitating an evaluation of practitioner knowledge and practice.
Purpose of the Study:
- To assess healthcare practitioners' awareness and ability to recognize early sarcoma presentations.
- To identify factors influencing sarcoma diagnosis and perceived barriers to timely work-up.
- To evaluate the need for targeted education and improved referral pathways.
Main Methods:
- A structured survey was administered to healthcare practitioners to assess knowledge of clinical features, investigations, and diagnostic delays.
- Data collected included practitioner demographics, training, experience, and patient load.
- Familiarity with guideline-based practice and confidence in recognizing red-flag symptoms were evaluated.
Main Results:
- Overall awareness of sarcoma was modest, with higher scores among those with prior sarcoma exposure, oncology training, and greater experience.
- Female practitioners and oncology nurses demonstrated higher awareness levels.
- Confidence in identifying warning signs correlated with familiarity with guideline-based practices, yet significant knowledge gaps persisted across specialties.
Conclusions:
- Healthcare practitioner awareness of sarcoma is insufficient for optimal early detection and management.
- Exposure alone does not guarantee adequate knowledge; targeted educational interventions are necessary.
- Improving recognition of early warning signs and establishing clear referral pathways are essential to reduce diagnostic delays for soft tissue and bone sarcomas.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...